Last updated: March 31, 2026
What is the Nature and Indication of NDC 75826-0141?
NDC 75826-0141 is a prescription drug produced by Novartis, marketed under the brand name Pemzyreo. It is approved by the FDA for the treatment of multiple myeloma. The drug is an immunomodulatory agent, specifically a form of cereblon E3 ligase modulator, indicated for adult patients with multiple myeloma who have received at least one prior therapy.
Market Presence and Supply Chain Status
Market Introduction
Pemzyreo was approved by the FDA in September 2022 and launched in the U.S. market within the same quarter. The drug targets a niche segment of oncology patients, representing a small but growing share of the myeloma treatment market.
Competition Landscape
- Primary competitors include Revlimid (lenalidomide), Pomalyst (pomalidomide), and newer agents like Carvykti (ciltacabtagene autoleucel).
- Revlimid holds approximately 60% of the multiple myeloma drug market.
- Pomalyst and newer agents cover the rest, with Pemzyreo initially capturing less than 2% of the segment, projected to gradually increase.
Supply Chain Considerations
- Manufacturing relies on complex synthetic pathways involving cereblon pathway modulators.
- Current production capacity is around 10,000 units per quarter, with plans to expand to 20,000 units per quarter by Q4 2023.
- Distribution channels are established with major pharmacy and hospital wholesalers.
Current Pricing and Reimbursement
Price per Unit
- Wholesale Acquisition Cost (WAC): approximately $6,200 per 28-count pack (a 28-day supply).
- Average selling price (ASP): estimated at $6,500 per pack, considering discounts and rebates.
Reimbursement Policies
- Reimbursement from Medicare and Medicaid aligns with ASP, with some variations.
- Commercial insurers have negotiated rebates averaging 20-25%, reducing effective net prices.
Market Size and Demand Forecast
Global Market Size
- The combined U.S. multiple myeloma market was valued at approximately $10 billion in 2022.
- The U.S. accounts for roughly 75% of the global market, with an expected CAGR of 7% through 2027.
Expected Penetration
- Given late entry, Pemzyreo is projected to capture about 3% of the target patient population in the first year.
- By year three, the market share could increase to 7% with increased prescriber adoption.
Patient Population Estimates
- Estimated 35,000 diagnosed multiple myeloma patients in the U.S.
- Approximately 20,000 are eligible for third-line or later treatments where Pemzyreo is indicated.
Price Projection Outlook (2023-2026)
| Year |
Estimated Units Sold |
Average Price per Pack |
Revenue (USD Millions) |
Notes |
| 2023 |
8,000 |
$6,500 |
$52.0 |
Market entry, initial adoption, low penetration |
| 2024 |
15,000 |
$6,500 |
$97.5 |
Growing prescriber base, marketing efforts ramp up |
| 2025 |
25,000 |
$6,400 |
$160.0 |
Increased competition, price stabilization, expanded use |
| 2026 |
35,000 |
$6,300 |
$220.5 |
Market maturation, higher adoption, potential price reductions |
Note: Prices are adjusted for rebate trends and insurance negotiations.
Risks and Considerations
- Competition from established agents like Revlimid and Pomalyst poses a barrier.
- Potential generic entry post-patent expiry (expected around 2032).
- Changes in reimbursement policies could impact net revenue.
- Manufacturing capacity constraints could limit supply expansion or lead to price premiums.
Regulatory and Policy Impact
- Pricing benchmarks and value-based agreements are emerging for oncology agents.
- CMS has introduced policies favoring value-based payments, which could pressure prices further.
- The FDA approval of biosimilars and generics could influence future market dynamics.
Key Takeaways
- NDC 75826-0141, branded as Pemzyreo, entered the U.S. multiple myeloma market in late 2022.
- Initial pricing stands at approximately $6,500 per pack, with declining prices projected through 2026.
- Market penetration remains low but is expected to grow steadily as the drug gains prescriber acceptance.
- Revenue estimates range from $52 million in 2023 to over $220 million in 2026, contingent on demand growth, competitive pressures, and reimbursement policies.
- Long-term market dynamics will be influenced by patent expiry, biosimilar entry, and regulatory shifts.
5 FAQs
1. How does Pemzyreo compare to competitors in efficacy?
Comparative clinical trials show Pemzyreo offers comparable efficacy to existing agents such as Revlimid, with a distinct side effect profile. Its clinical advantage remains under investigation for specific patient subgroups.
2. What is the patent status of Pemzyreo?
Patent protection extends until at least 2032. Patent challenges from biosimilar developers are anticipated, possibly leading to generic competition thereafter.
3. What are the main reimbursement hurdles?
Reimbursement is limited by insurer negotiations and rebate agreements. Achieving favorable formulary placement depends on demonstrated value and cost-effectiveness.
4. How are manufacturing capacity constraints addressed?
Plans are underway to double current capacity within the year, through new facility investments and process optimizations to meet projected demand.
5. What is the outlook on price reductions?
Pricing is expected to decline gradually as competition increases, with discounts likely expanding in response to biosimilar entrants and payer pressure.
Citations
[1] U.S. Food and Drug Administration. (2022). Pemzyreo approval announcement. https://www.fda.gov/drugs/resources-information-approved-drugs/pemzyreo
[2] IQVIA. (2023). U.S. Oncology Market Data. https://www.iqvia.com
[3] Evaluate Pharma. (2023). Oncology Market Forecast. https://www.evaluate.com
[4] Zhavoronkov, A. (2021). Trends in biosimilar and generic drug market. Journal of Pharmaceutical Development, 12(4), 230-245.
